|
Volumn 82, Issue 8, 2014, Pages 725-729
|
Confidentiality in preclinical Alzheimer disease studies When research and medical records meet
|
Author keywords
[No Author keywords available]
|
Indexed keywords
AMYLOID PROTEIN;
ANTIAMYLOID AGENT;
BIOLOGICAL MARKER;
NOOTROPIC AGENT;
PLACEBO;
UNCLASSIFIED DRUG;
ALZHEIMER DISEASE;
AMERICANS WITH DISABILITIES ACT;
ARTICLE;
CERTIFICATION;
CLINICAL PRACTICE;
CLINICAL RESEARCH;
CLINICAL TRIAL (TOPIC);
CONFIDENTIALITY;
DISABILITY;
EDUCATION PROGRAM;
ELECTRONIC MEDICAL RECORD;
EMPLOYMENT;
EMPLOYMENT DISCRIMINATION;
HEALTH CARE POLICY;
HEALTH INSURANCE;
HUMAN;
INTERPERSONAL COMMUNICATION;
LONG TERM CARE;
MEDICAL INFORMATION;
MEDICARE;
NERVOUS SYSTEM INJURY;
NEUROPATHOLOGY;
PRIORITY JOURNAL;
PRIVATE HEALTH INSURANCE;
RESEARCH SUBJECT;
RISK FACTOR;
STUDY DESIGN;
ALZHEIMER DISEASE;
BIOLOGICAL MARKERS;
CONFIDENTIALITY;
DRUG EVALUATION, PRECLINICAL;
HUMANS;
INSURANCE, HEALTH;
MEDICAL RECORDS;
RESEARCH DESIGN;
RISK;
|
EID: 84895800589
PISSN: 00283878
EISSN: 1526632X
Source Type: Journal
DOI: 10.1212/WNL.0000000000000153 Document Type: Article |
Times cited : (48)
|
References (13)
|